Dermatophytosis is one of the leading causes of visits to the dermatology department, especially in India, where the hot and humid climate favours fungal acquisition and perpetuation. Usual modalities of treatment include the use of either oral or topical antifungals or a combination of both, depending on the severity and extent of
infection as well as the type of causative organism. But recently,
steroid-modified
dermatophytosis, an iatrogenically perpetuated
dermatophytosis caused by the indiscriminate use of topical
corticosteroids has emerged as a troublesome epidemic. We planned a cost-of-illness analysis of superficial
dermatophytosis comparing the direct healthcare costs in
steroid-naive and
steroid-modified
dermatophytosis. In our study, the average total cost of treatment for
steroid-naive and
steroid-modified
dermatophytosis was found to be rupees (Rs) 2172.42 and Rs 3770.61 respectively, meaning that the cost for patients who used topical
steroids is an additional 40% on average for treatment, when compared with the cost for patients who are
steroid naive. The need for more consultations, investigations (relating to atypical presentation) and extended
duration of treatment with higher-grade antifungals were found to contribute to the increased financial burden in
steroid-modified
dermatophytosis.